Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase II study findings on AZD5363 plus paclitaxel vs placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (Abstract 1007).
Danh Pham, MD, of the James Graham Brown Cancer Center, University of Louisville, discusses his findings using a registry on the low rates of screening with low-dose computed tomography, despite its potential to prevent thousands of lung cancer deaths each year (Abstract 6504).
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discuss the efficacy of sacituzumab govitecan for treatment-refractory hormone receptor–positive/HER2-negative metastatic breast cancer (Abstract 1004).
Howard S. Hochster, MD, of Rutgers-Cancer Institute of New Jersey, discusses study findings on irinotecan and cetuximab vs irinotecan, cetuximab, and ramucirumab as second-line therapy of advanced colorectal cancer following oxaliplatin and bevacizumab-based therapy (Abstract 3504).
Raymond U. Osarogiagbon, MBBS, of Baptist Cancer Center, discusses a kit used in non–small cell lung cancer resection that improves staging quality and overall survival without adding to morbidity of curative surgery (Abstract 8502).
Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, discusses phase III findings on ibrutinib/rituximab vs placebo/rituximab in Waldenström’s macroglobulinemia (Abstract 8003).
